Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults

Clinical Infectious Diseases

Volumn 26, Issue 6, 1998, Pages 1312-1323

  Aubier, M ^a   Verster, R ^b   Regamey, C ^b   Geslin, P ^b   Vercken, J B ^b  

^a Clinique Pneumologique   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; PLACEBO; SPARFLOXACIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHOTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; VOMITING;

EID: 0031840657     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516366     Document Type: Article

References (29)

1. Ellner JJ. Management of acute and chronic respiratory tract infections. Am J Med 1988;85(suppl 3A):2-5.
2. Fang GD, Fine M, Orloff J. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multi-centre study of 359 cases. Medicine (Baltimore) 1990;69:307-16.
3. Fick RB, Reynolds HY. Changing spectrum of pneumonia - news media creation or clinical reality? Am J Med 1983;74:1-8.
4. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact. Am J Med 1985;78: 32-7.
5. Woodhead MA, MacFarlane JT, McCracken JS, Rose DX Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987;March 21:671-4.
6. MacFarlane J. An overview of community acquired pneumonia with lessons learned from the British Thoracic Society Study. Semin Respir Infect 1994;9:153-65.
7. Campbell GD. Overview of community-acquired pneumonia: prognosis and clinical features. Med Clin North Am 1994;78:1035-48.
8. Ginesu F, Pirina P. Etiology and risk factors of adult pneumonia. J Chemother 1995;7:277-85.
9. Kemper CA, Deresinski SC. Diagnosis and management of pneumonia. Pharmacotherapy 1991;11:84S-9S.
10. La Force FM. Antibacterial therapy for lower respiratory tract infections in adults: a review. Clin Infect Dis 1992;14(suppl 2):S233-7.
11. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990;3:171-96.
12. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34:2075-80.
13. Ortqvist A, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J 1990;3:1105-13.
14. Torres A, El-Ebiary M. Relevance of Chlamydia pneumoniae in community acquired respiratory infections. Eur Respir J 1993;6:7-8.
15. Guidelines, for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418-26.
16. Malmborg AS, Ahlen S. In vitro activity of sparfloxacin compared with ciprofloxacin and ofioxacin against respiratory tract pathogens. Chemotherapy 1993;39:32-5.
17. Baquero F, Canton R. In-vitro activity of sparfioxacin in comparison with currently available antimicrobials against respiratory tract pathogens. J Antimicrob Chemother 1996;37(suppl A):1-18.
18. Montay G. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. J Antimicrob Chemother 1996;37(suppl A):27-39.
19. Wise R, Honeyboume D. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother 1996; 37(suppl A):57-63.
20. El Refaie, Dulake C. Counter-current immunoelectrophoresis for the diagnosis of pneumococcal chest infection. J Clin Pathol 1975;28:801-6.
21. Wreghitt TG, Sillis MA. μ-Capture ELISA for detecting Mycoplasma pneumoniae IgM: comparison with indirect immunofluorescence and indirect ELISA. Journal of Hygiene (Cambridge) 1985;94:217-27.
22. Harrison TG, Taylor AG. Indirect immunofluorescent antibody test for the detection of antibodies against Legionella pneumophila serogroup 1. In: Harrison TG, Taylor AG, eds. A laboratory manual for Legionella. Chichester, England: John Wiley & Son, 1988:113-6.
23. Bradstreet CMP, Taylor CED. Technique of complement-fixation test applicable to the diagnosis of virus diseases. Monthly Bull Ministry Health & PHLS 1962;21:94-104.
24. Genevois E, Lelouer V, Vercken J-B, Caillon R. Study design, methodology and statistical analyses in the clinical development of sparfloxacin. J Antimicrob Chemother 1996;37(suppl A):65-72.
25. Jaillon P, Morganroth J, Brumpt I, et al. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother 1996;37(suppl A):65-72.
26. Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 1995;8:1999-2007.
27. Moine P, Vercken J-B, Chevret S, et al. Severe community-acquired pneumonia: etiology, epidemiology, and prognosis factors. Chest 1994;105: 1487-95.
28. Freiden TR, Mangi RJ. Inappropriate use of oral ciprofloxacin. JAMA 1990;264:1438-40.
29. Cruciani M, Bassetti D. The fluoroquinolones as treatment for infections caused by gram-positive infections. J Antimicrob Chemother 1994;33: 403-17.